Can a weekly pill and weight lifting rebuild aging bones?

NCT ID NCT07191353

Recruiting now Disease control Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a weekly dose of everolimus (a drug similar to rapamycin), resistance training three times a week, or both together can improve bone formation in women aged 60-75 with low bone mass. Researchers will measure bone markers, density, and muscle function over 24 weeks. The goal is to find a safe way to prevent osteoporosis without long-term medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Everolimus (a rapamycin analog) and resistance training
What this could lead to: If successful, this could point toward a drug-exercise combination to strengthen bones and reduce fracture risk in older women.
What could go wrong: This is a small, early-phase trial with 148 participants. The drug may cause side effects, and results may not apply to all women. The combination might not work better than exercise alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic osteoporosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY OSTEOPENIA OSTEOPOROSIS RISK

Contacts and locations

Locations

Department of Endocrinology, Odense University Hospital
RECRUITING

Odense, Region Syddanmark, 5000, Denmark
Institute of Sports Medicine, Bispebjerg Hospital
RECRUITING

Bispebjerg, Region Sjælland, 2200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.